J Bradley Layton1,2, Dongmei Li1, Christoph R Meier3, Julie L Sharpless4, Til Stürmer1, M Alan Brookhart1. 1. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. RTI Health Solutions, Research Triangle Park, NC, USA. 3. Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. 4. Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract
CONTEXT: Exogenous testosterone administration may affect blood clotting, polycythaemia, and may increase atherosclerosis, though any association with cardiovascular events is unclear. While the literature is inconclusive, some studies have suggested testosterone use may increase short-term risk of cardiovascular events and stroke, and injection testosterone may convey higher risks than other dosage forms. OBJECTIVE: We sought to evaluate the short-term cardiovascular risk of receiving injection testosterone. DESIGN: We conducted a case-crossover analysis comparing injection testosterone exposure in the 7 days prior to an outcome event to referent windows in the past to estimate the acute association of cardiovascular outcomes with the receipt of testosterone injections. PATIENTS: We identified adult male testosterone users hospitalized with myocardial infarction (MI), stroke or a composite of MI, stroke or unstable angina in US commercial claims (2000-2013) or Medicare (2007-2010) databases. MEASUREMENTS: We identified testosterone use for the patients from pharmacy dispensing claims or in-office procedure codes in the insurance billing data. RESULTS: We identified 2898 commercially insured men with events and recent testosterone use, and 339 from Medicare. Injected testosterone was associated with an increased risk of adverse events (composite outcome of myocardial infarction, stroke or unstable angina) in the immediate postinjection period for the older, Medicare population only: commercial insurance, odds ratios (OR) = 0.98 (95% confidence intervals [CI]: 0.86-1.12); Medicare, OR = 1.45 (1.07, 1.98). This association was either greatly attenuated or not present when evaluating receipt of any testosterone dosage forms (injection, gel, patch, implant): commercial insurance, OR = 1.01 (0.92, 1.11); Medicare, OR = 1.26 (95% CI: 0.98-1.63). CONCLUSIONS: Testosterone injections were uniquely associated with short-term risk of acute cardio- and cerebrovascular events in older adult men following injection receipt.
CONTEXT: Exogenous testosterone administration may affect blood clotting, polycythaemia, and may increase atherosclerosis, though any association with cardiovascular events is unclear. While the literature is inconclusive, some studies have suggested testosterone use may increase short-term risk of cardiovascular events and stroke, and injection testosterone may convey higher risks than other dosage forms. OBJECTIVE: We sought to evaluate the short-term cardiovascular risk of receiving injection testosterone. DESIGN: We conducted a case-crossover analysis comparing injection testosterone exposure in the 7 days prior to an outcome event to referent windows in the past to estimate the acute association of cardiovascular outcomes with the receipt of testosterone injections. PATIENTS: We identified adult male testosterone users hospitalized with myocardial infarction (MI), stroke or a composite of MI, stroke or unstable angina in US commercial claims (2000-2013) or Medicare (2007-2010) databases. MEASUREMENTS: We identified testosterone use for the patients from pharmacy dispensing claims or in-office procedure codes in the insurance billing data. RESULTS: We identified 2898 commercially insured men with events and recent testosterone use, and 339 from Medicare. Injected testosterone was associated with an increased risk of adverse events (composite outcome of myocardial infarction, stroke or unstable angina) in the immediate postinjection period for the older, Medicare population only: commercial insurance, odds ratios (OR) = 0.98 (95% confidence intervals [CI]: 0.86-1.12); Medicare, OR = 1.45 (1.07, 1.98). This association was either greatly attenuated or not present when evaluating receipt of any testosterone dosage forms (injection, gel, patch, implant): commercial insurance, OR = 1.01 (0.92, 1.11); Medicare, OR = 1.26 (95% CI: 0.98-1.63). CONCLUSIONS:Testosterone injections were uniquely associated with short-term risk of acute cardio- and cerebrovascular events in older adult men following injection receipt.
Authors: Jacques Baillargeon; Randall J Urban; Yong-Fang Kuo; Kenneth J Ottenbacher; Mukaila A Raji; Fei Du; Yu-Li Lin; James S Goodwin Journal: Ann Pharmacother Date: 2014-07-02 Impact factor: 3.154
Authors: Cindy N Roy; Peter J Snyder; Alisa J Stephens-Shields; Andrew S Artz; Shalender Bhasin; Harvey J Cohen; John T Farrar; Thomas M Gill; Bret Zeldow; David Cella; Elizabeth Barrett-Connor; Jane A Cauley; Jill P Crandall; Glenn R Cunningham; Kristine E Ensrud; Cora E Lewis; Alvin M Matsumoto; Mark E Molitch; Marco Pahor; Ronald S Swerdloff; Denise Cifelli; Xiaoling Hou; Susan M Resnick; Jeremy D Walston; Stephen Anton; Shehzad Basaria; Susan J Diem; Christina Wang; Stanley L Schrier; Susan S Ellenberg Journal: JAMA Intern Med Date: 2017-04-01 Impact factor: 21.873
Authors: Eric Bachman; Thomas G Travison; Shehzad Basaria; Maithili N Davda; Wen Guo; Michelle Li; John Connor Westfall; Harold Bae; Victor Gordeuk; Shalender Bhasin Journal: J Gerontol A Biol Sci Med Sci Date: 2013-10-24 Impact factor: 6.053
Authors: Julie C Lauffenburger; Akhila Balasubramanian; Joel F Farley; Cathy W Critchlow; Cynthia D O'Malley; Mary T Roth; Virginia Pate; M Alan Brookhart Journal: Pharmacoepidemiol Drug Saf Date: 2013-05-21 Impact factor: 2.890
Authors: Jacques Baillargeon; Randall J Urban; Kenneth J Ottenbacher; Karen S Pierson; James S Goodwin Journal: JAMA Intern Med Date: 2013-08-12 Impact factor: 21.873
Authors: Mark A Hlatky; Roberta M Ray; Dale R Burwen; Karen L Margolis; Karen C Johnson; Anna Kucharska-Newton; JoAnn E Manson; Jennifer G Robinson; Monika M Safford; Matthew Allison; Themistocles L Assimes; Anthony A Bavry; Jeffrey Berger; Rhonda M Cooper-DeHoff; Susan R Heckbert; Wenjun Li; Simin Liu; Lisa W Martin; Marco V Perez; Hilary A Tindle; Wolfgang C Winkelmayer; Marcia L Stefanick Journal: Circ Cardiovasc Qual Outcomes Date: 2014-01-07
Authors: William D Finkle; Sander Greenland; Gregory K Ridgeway; John L Adams; Melissa A Frasco; Michael B Cook; Joseph F Fraumeni; Robert N Hoover Journal: PLoS One Date: 2014-01-29 Impact factor: 3.240
Authors: Molly M Shores; Thomas J Walsh; Anna Korpak; Chloe Krakauer; Christopher W Forsberg; Alexandra E Fox; Kathryn P Moore; Susan R Heckbert; Mary Lou Thompson; Nicholas L Smith; Alvin M Matsumoto Journal: J Am Heart Assoc Date: 2021-08-21 Impact factor: 5.501